September 24, 2018
NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark  this link  for your convenience.

 
Robert A. Burger, M.D.

NRG-GY003: The Addition of a CTLA4 Targeted Therapy to a PD-1 Targeted Therapy Could Benefit Women with Ovarian Cancer    Read More

The NRG Oncology publications page on the website has moved. Read more

AMENDMENTS
BRAIN
NRG-BN005: Amendment 1; version date: August 22, 2018 (posted on CTSU). Please contact the CTSU Help Desk for tracked protocol documents.

GYNECOLOGIC
NRG-GY007: Amendment 6; version date: July 30, 2018 (posted on  NRG Oncology). Please review the “Additional Optional Biospecimen Collection” Memo, dated May 14, 2018 (under Correspondence & Instructions — Other)

HEAD & NECK
NRG-HN003:  Amendment 4; version date: August 24, 2018 (posted on NRG Oncology)

LUNG
NRG-LU002: Amendment 1-2 – Attention sites in Canada – This study does not require a CTA to be submitted to Health Canada; therefore, no NOL will be issued. Sites may continue with IRB/REB submission.

OTHER PROTOCOL NOTICES
1. Children’s Oncology Group Protocol AGCT1531: “A Phase III Trial of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors” is open to patient entry. It is available on the CTSU menu with Dr. Allan Covens as NRG Champion. Please enroll your eligible patients to this important trial. Enrollment credited to NRG Oncology will count towards membership requirements.

2. BREAST
RTOG 1119: Study Memorandum to Encourage Accrual Completion dated September 24, 2018 (posted on CTSU)

3. GYNECOLOGIC
GOG-0210: Biospecimen Submission
Please complete and submit any overdue outstanding biospecimen transmittal forms (i.e., Form SP) in SEDES immediately. Overdue SP forms not completed by Monday, October 1, 2018, will be subject to query. If you will be submitting frozen biospecimens, please contact the NRG BB-Columbus ( bpcbank@nationwidechildrens.org) to request a biospecimen kit.

If you will not be submitting biospecimens, please complete Form SP indicating “not collected.”

Note regarding Recurrent Biospecimens: SP forms for recurrent biospecimens do not need to be completed if the patient has not yet recurred. If the patient has recurred and the specimens will be submitted, please do so as soon as possible. If recurrent specimens will not be submitted, please complete Form SP indicating “not collected.”

4. VTOC TRAINING
The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, and NRG-CC004. Space is limited so register now and reserve your seat.  The next webinar training is scheduled for October 10, 2018.

 

DRUG SAFETY UPDATES
Safety updates have been issued for the following studies:

DRUG NAME

PROTOCOL

WEBSITE FOR SAFETY REPORTS

AMG 386

RTOG 1122

NRG

Bevacizumab

GOG-0213

GOG-0262

NRG-GY012

CTSU

CTSU

CTSU

Durvalumab

NRG-HN004

CTSU

Ipilimumab

NRG-BN002

NRG-GY003

NRG

NRG

Nivolumab

NRG-BN002

NRG-GY003

NRG

NRG

Olaparib

NRG-GY004

NRG-GY005

CTSU

CTSU

 

 

THE ADDITION OF A CTLA4 TARGETED THERAPY TO A PD-1 TARGETED THERAPY COULD BENEFIT WOMEN WITH OVARIAN CANCER
An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival hazard rates for women with recurrent epithelial ovarian cancer. These results were presented as a late-breaking abstract oral presentation at the 17th Biennial Meeting of the International Gynecological Cancer Society (IGCS) in Kyoto, Japan. Read more

APPLICATIONS FOR NRG ONCOLOGY CLINICAL RESEARCH COORDINATOR MENTOR PROGRAM NOW OPEN
The NRG Oncology Mentorship Working Group is now accepting applications for mentors. The primary goal of the NRG Oncology Research Coordinator Mentor Program is to support new CTNs and CRAs in their NRG roles at NRG Oncology member institutions. A description of the mentor program and the qualifications can be found on the NRG Oncology website under the Nurses & CRAs tab . Submit the application on or before October 26, 2018. Please email your application to the NRG Oncology PSC mailbox, nrg-psc@NRGOncology.org:  Subject line: “Mentorship”.

 

NEW LOCATION ON WEBSITE
Please note that the NRG Oncology Publications tab on the website has relocated. You can now find the publications section under the Clinical Trials tab of the website:  nrgoncology.org/Clinical-Trials/Publications

PUBLICATIONS REMINDERS
Please note the following upcoming meeting and abstract submission deadline dates

Upcoming Meetings
American Society for Radiation Oncology (ASTRO); Oct 21-24, 2018; San Antonio, TX

European Society for Medical Oncology (ESMO); Oct 19-23, 2018; Munich, Germany

PA Breast Cancer Coalition (PBCC); October 19, 2018; Harrisburg, PA

Upcoming Abstract Submission Deadlines
American Society of Clinical Oncology (ASCO) GI; Jan 17-19, 2019; San Francisco, CA; meeting abstracts submission deadline Sep 25, 2018

American Society of Clinical Oncology (ASCO) GU; Feb 14-16, 2019; San Francisco, CA; due to publications committee Oct 9, 2018; meeting abstracts submission deadline Oct 23, 2018

European Society for Radiotherapy and Oncology (ESTRO); Apr 26-30, 2019; Milan, Italy; due to publications committee Oct 8, 2018; meeting abstracts submission deadline Oct 22, 2018

Society of Gynecologic Oncology (SGO); Mar 16-19, 2019; Honolulu, HI; deadline for International abstracts 12-12-18; deadline for LBA 12-3-18 to 1-7-19

Society of Surgical Oncology (SSO); Mar 27-30, 2019;  San Diego, CA; meeting abstracts submission deadline Oct 1, 2018

NRG Oncology is proud to be an active participant of #CancerMoonShot.
View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse